CN111011863A - Medical electrolyte composition and preparation method thereof - Google Patents
Medical electrolyte composition and preparation method thereof Download PDFInfo
- Publication number
- CN111011863A CN111011863A CN201911363862.XA CN201911363862A CN111011863A CN 111011863 A CN111011863 A CN 111011863A CN 201911363862 A CN201911363862 A CN 201911363862A CN 111011863 A CN111011863 A CN 111011863A
- Authority
- CN
- China
- Prior art keywords
- percent
- oligosaccharide
- composition
- maltodextrin
- citric acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 46
- 239000003792 electrolyte Substances 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 63
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 29
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 26
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 25
- 239000011707 mineral Substances 0.000 claims abstract description 25
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 24
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 24
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 24
- 229930091371 Fructose Natural products 0.000 claims abstract description 23
- 239000005715 Fructose Substances 0.000 claims abstract description 23
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims abstract description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 21
- 235000013305 food Nutrition 0.000 claims abstract description 20
- 150000001875 compounds Chemical class 0.000 claims abstract description 18
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 15
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 15
- 239000000243 solution Substances 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 11
- 230000001954 sterilising effect Effects 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 229920001353 Dextrin Polymers 0.000 claims description 6
- 239000004375 Dextrin Substances 0.000 claims description 6
- 239000007853 buffer solution Substances 0.000 claims description 6
- 239000002131 composite material Substances 0.000 claims description 6
- 235000019425 dextrin Nutrition 0.000 claims description 6
- 238000011049 filling Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- 239000011734 sodium Substances 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 238000007789 sealing Methods 0.000 claims description 3
- 238000012859 sterile filling Methods 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 abstract description 21
- 239000008280 blood Substances 0.000 abstract description 21
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 15
- 235000000346 sugar Nutrition 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 12
- 235000003642 hunger Nutrition 0.000 abstract description 9
- 150000002772 monosaccharides Chemical class 0.000 abstract description 7
- 230000013872 defecation Effects 0.000 abstract description 6
- 150000004676 glycans Chemical class 0.000 abstract description 6
- 229920001282 polysaccharide Polymers 0.000 abstract description 6
- 239000005017 polysaccharide Substances 0.000 abstract description 6
- 230000035807 sensation Effects 0.000 abstract description 6
- 235000019615 sensations Nutrition 0.000 abstract description 6
- 238000004140 cleaning Methods 0.000 abstract description 5
- 235000019627 satiety Nutrition 0.000 abstract description 5
- 230000036186 satiety Effects 0.000 abstract description 5
- 230000035622 drinking Effects 0.000 abstract description 4
- 206010022489 Insulin Resistance Diseases 0.000 abstract description 3
- 230000002035 prolonged effect Effects 0.000 abstract description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 3
- 230000004044 response Effects 0.000 abstract description 2
- 150000008163 sugars Chemical class 0.000 abstract description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 24
- 239000008103 glucose Substances 0.000 description 24
- 230000000052 comparative effect Effects 0.000 description 15
- 241000894006 Bacteria Species 0.000 description 14
- 230000009286 beneficial effect Effects 0.000 description 11
- 239000001508 potassium citrate Substances 0.000 description 9
- 229960002635 potassium citrate Drugs 0.000 description 9
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 9
- 235000011082 potassium citrates Nutrition 0.000 description 9
- 239000001509 sodium citrate Substances 0.000 description 9
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 230000002980 postoperative effect Effects 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 235000013406 prebiotics Nutrition 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000009499 grossing Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 241000186000 Bifidobacterium Species 0.000 description 2
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 2
- 241000186016 Bifidobacterium bifidum Species 0.000 description 2
- 241000186012 Bifidobacterium breve Species 0.000 description 2
- 241001608472 Bifidobacterium longum Species 0.000 description 2
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 description 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 2
- 244000199866 Lactobacillus casei Species 0.000 description 2
- 235000013958 Lactobacillus casei Nutrition 0.000 description 2
- 241000186840 Lactobacillus fermentum Species 0.000 description 2
- 241000186869 Lactobacillus salivarius Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 2
- 229940004120 bifidobacterium infantis Drugs 0.000 description 2
- 229940009291 bifidobacterium longum Drugs 0.000 description 2
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 206010016766 flatulence Diseases 0.000 description 2
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 2
- 229940107187 fructooligosaccharide Drugs 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 2
- 229940017800 lactobacillus casei Drugs 0.000 description 2
- 229940012969 lactobacillus fermentum Drugs 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 229960003975 potassium Drugs 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000010444 Acidosis Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 208000005156 Dehydration Diseases 0.000 description 1
- 206010067715 Gastrointestinal sounds abnormal Diseases 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010067268 Post procedural infection Diseases 0.000 description 1
- 208000035965 Postoperative Complications Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- -1 diabetic patients Chemical compound 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000004121 glycogenesis Effects 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 230000004140 ketosis Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
- A23L29/35—Degradation products of starch, e.g. hydrolysates, dextrins; Enzymatically modified starches
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/25—Synthetic polymers, e.g. vinylic or acrylic polymers
- A23L33/26—Polyol polyesters, e.g. sucrose polyesters; Synthetic sugar polymers, e.g. polydextrose
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a medical electrolyte composition, which comprises the following components in percentage by mass: 8 to 22 percent of maltodextrin, 2 to 6 percent of crystalline fructose, 0.3 to 3 percent of oligosaccharide, 0.1 to 0.7 percent of compound mineral, 0.2 to 1 percent of citric acid, 0 to 0.05 percent of food essence and the balance of water. The composition of the invention mixes monosaccharide (fructose) and polysaccharide (maltodextrin and oligosaccharide) for use, and various sugars are absorbed by human body one by one to slowly release energy by reducing the content of the monosaccharide, so that blood sugar rises slowly after drinking, and the duration of satiety is prolonged. The composition of the invention can smooth blood sugar of a patient before operation, reduce hunger sensation and facilitate defecation and cleaning of intestinal tracts so as to improve and maintain the living state of the patient and reduce fear and tension of the patient before operation. In addition, the insulin resistance response of the patient after the operation has no obvious difference from the effect of the traditional intestinal tract preparation method.
Description
Technical Field
The invention relates to a medical electrolyte composition and a preparation method thereof, belonging to the technical field of medical nutritional food and preparation methods thereof.
Background
Diet prohibition before selective operation is used for reducing the capacity and acidity of gastric contents and preventing vomiting and aspiration during anesthesia. At present, textbooks in China still use the traditional view: adult patients with selective surgery are fasted for 8-12 hours before operation and forbidden to drink for 4 hours. However, in recent years, it has been discovered that the actual fasting time of more than 10h and the drinking prohibition time of more than 6h before the operation can cause the adverse reactions of the patients, such as thirst, hunger, anxiety, dehydration, hypoglycemia and the like. The blood sugar of the organism is reduced under the state of food and drink prohibition, which leads to the reduction of insulin secretion, the increase of glucagon, growth hormone and catecholamine secretion, the acceleration of glycogen decomposition and the increase of glycogenesis. Long-term drinking prohibition promotes muscle protein mobilization, hepatic glucose isomerization and increased glucose production to supplement blood sugar. The decomposition of fat in the body is increased, and becomes the main energy source of the body. Therefore, in the early period of fasting, if the glucose can be supplemented in time, the xenogenesis of the protein can be obviously reduced, and the protein is saved; moreover, the supplement of glucose can prevent ketosis caused by fat decomposition and reduce the incidence of acidosis. Surgery is a trauma to the body and can lead to post-operative insulin resistance. It is an important metabolic factor affecting postoperative recovery, increases the productivity and fatality rate of postoperative complications such as bacteremia and infection, and has become an important influencing factor for determining the length of postoperative hospitalization.
The ideal bowel preparation is: the colon is completely empty, antibiotics are not needed, the number of bacteria in the intestinal cavity is reduced, electrolyte balance is maintained, the pain of a patient is small, and the nursing time is shortened. The good preoperative preparation can clean the intestinal tract, is convenient for surgical operation, reduces the quantity of intestinal bacteria, promotes wound healing, and reduces the occurrence rate of pollution and postoperative infection. In order to enable a patient to be in a good functional state before an operation, on the basis of shortening the time of food and drink prohibition, certain clinical studies are to orally take glucose and electrolyte (namely 50g of glucose and 5g of sodium chloride added with 500mL of water) or carbohydrate beverage (12.5g of carbohydrate per 100mL) or carbohydrate beverage before an operation for the patient, after the patient drinks the electrolyte-containing solution in a short time, intestinal tract water can be absorbed additionally due to osmotic pressure in the intestinal tract, watery stool is discharged downwards, the whole colon or even the tail end of the ileum can be flushed cleanly, the effect is fast, the irritation to the intestinal tract is small, and a good effect is obtained.
However, this method requires a relatively large amount of electrolyte-sodium (5g/500mL) and contains a relatively high amount of glucose, and is not suitable for patients who need to control the intake of sodium and glucose, such as diabetic patients, and in addition, the preoperative patients are bedridden for a relatively long time, have little walking, have slow intestinal motility, and are excreted by osmotic pressure generated by the electrolyte, and the efficiency is relatively slow. Moreover, the carbohydrate beverage provides energy for patients through monosaccharide (glucose or fructose) and polysaccharide (maltodextrin), the monosaccharide and the single polysaccharide (maltodextrin) can be quickly absorbed and utilized by human bodies, the energy release is quick, and the satiety duration is short.
In the literature "comparison of the hyperglycemic effect of different carbohydrates" (release of the journal of preventive medicine, volume 35, 9, 2017), the test results show that: the maltodextrin has obvious and mild blood sugar increasing effect, the fructose has mild blood sugar increasing effect, and the oligosaccharide and the like have no obvious blood sugar increasing effect on the body in a short time. The present invention is based on the finding that a medical electrolyte composition is provided which is capable of smoothing blood glucose, reducing hunger sensation and helping defecation and cleaning the intestine of a patient before an operation.
In the document "comparison of prebiotic functions and effects of different functional oligosaccharides" (china journal of food additives, 2009), the results of comparative experiments show that: among the proliferation effects of fructo-oligosaccharide, galacto-oligosaccharide and isomalto-oligosaccharide on beneficial bacteria, galacto-oligosaccharide is the only prebiotic which can be utilized by 9 beneficial bacteria (bifidobacteria, namely bifidobacterium infantis, bifidobacterium breve, bifidobacterium adolescentis, bifidobacterium bifidum and bifidobacterium longum, lactobacillus, namely lactobacillus acidophilus, lactobacillus casei, lactobacillus fermentum and lactobacillus salivarius) in the human intestines, and is more beneficial to the proliferation of the beneficial bacteria in the intestines, thereby providing guarantee for the immunity enhancement of postoperative patients.
The document "A comparative in vitro evaluation of the transfer property of the biological oligonucleotides" (Journal of Applied Microbiology 2001) describes comparative experiments: in the capability (time and acid yield) of producing organic acids (lactic acid, acetic acid, propionic acid and butyric acid) by fructo-oligosaccharide, galacto-oligosaccharide, xylo-oligosaccharide and isomalto-oligosaccharide, the acid yield of galacto-oligosaccharide is higher in a short time (5h) than that of other oligosaccharides, a higher content level can be maintained in a longer time (24h), and the higher intestinal acidity can prevent colonization of harmful bacteria in the intestinal tract and is more beneficial to discharge the harmful bacteria out of the body. Meanwhile, the gas production is compared: the gas yield of the galacto-oligosaccharides is relatively minimum in the galacto-oligosaccharides, the inulin, the xylo-oligosaccharides and the soybean oligosaccharides, so that the patients are less disturbed by bad feelings such as intestinal flatulence, rugitus and the like caused by the proliferation of neutral bacteria.
Disclosure of Invention
The present invention has been made to overcome the above-mentioned disadvantages of the prior art and an object of the present invention is to provide a medical electrolyte composition which can smooth blood glucose level before operation, reduce hunger sensation and facilitate defecation and intestinal tract cleaning for a patient, and a method for preparing the same.
In order to achieve the purpose, the invention adopts the technical scheme that: a medical electrolyte composition comprises the following components in percentage by mass: 8 to 22 percent of maltodextrin, 2 to 6 percent of crystalline fructose, 0.3 to 3 percent of oligosaccharide, 0.1 to 0.7 percent of compound mineral, 0.2 to 1 percent of citric acid, 0 to 0.05 percent of food essence and the balance of water.
Oligosaccharide is water-soluble dietary fiber, has been approved by more than 50 countries as a health food ingredient to use so far, is used as one of dietary fiber sources or prebiotics components, and has the functions of maintaining the normal functions of intestinal tracts and proliferating beneficial bacteria in the intestinal tracts to reduce harmful bacteria after being eaten. The oligosaccharide and the compound mineral substance are used together, and can help empty the deficient colon through the combined action of absorbing intestinal water.
In the examples, since the product is for medical use, the more specific the composition is required, the better, the higher the purity of the oligosaccharide is required, the better the oligosaccharide is a compound, the purity of the oligosaccharide is preferably 80% -100% of the total weight of dry matter; in some embodiments, more preferably 81% to 99%; in some embodiments, more preferably 82% to 98%; in some embodiments, more preferably 83% to 97%; in some embodiments, more preferably 84% to 96%; in some embodiments, more preferably 85% to 95%; in some embodiments, more preferably 86% to 94%; in some embodiments, more preferably 87% to 93%; in some embodiments, more preferably 88% to 92%; in some embodiments, more preferably 89% to 91%.
In the composition of the invention, the content of polysaccharide is higher than that of monosaccharide; in the polysaccharide, the content of dextrin is higher than that of oligosaccharide. The invention limits the mass percentage of each sugar to be: 8 to 22 percent of maltodextrin, 2 to 6 percent of crystalline fructose and 0.3 to 3 percent of oligosaccharide, so that the composition has continuous and mild effect on blood sugar. Oligosaccharide is added to promote intestinal peristalsis, and meanwhile, the addition amount of the compound mineral substances (sodium and potassium) is 0.1-0.7%, which is also beneficial to cleaning intestinal tracts.
As a preferred embodiment of the composition, the composition comprises the following components in percentage by mass: 9.8% of maltodextrin, 2.5% of crystalline fructose, 1.5% of oligosaccharide, 0.15% of compound mineral, 0.5% of citric acid, 0.01% of food essence and the balance of water.
In a preferred embodiment of the composition of the present invention, the oligosaccharide is at least one of galactooligosaccharide, mannose oligomer, xylose oligomer and resistant dextrin. The galactooligosaccharide is the only prebiotic which can be utilized by 9 beneficial bacteria (bifidobacteria, namely bifidobacterium infantis, bifidobacterium breve, bifidobacterium adolescentis, bifidobacterium bifidum and bifidobacterium longum, lactobacillus, namely lactobacillus acidophilus, lactobacillus casei, lactobacillus fermentum and lactobacillus salivarius) in the intestines of the human body, is more beneficial to the proliferation of the beneficial bacteria in the intestines, and provides guarantee for the immunity enhancement of postoperative patients. The acid amount of the galacto-oligosaccharide is higher than that of other oligosaccharides in a short time (5h), and a higher content level can be maintained in a longer time (24h), and the higher acidity of the intestinal tract can prevent colonization of harmful bacteria in the intestinal tract and is more helpful for discharging the harmful bacteria out of the body; and the gas production of galactooligosaccharides is relatively minimal, which can make patients less troubled by bad feelings such as flatulence and borborygmus due to the proliferation of neutrophiles.
As a preferred embodiment of the composition of the present invention, the complex mineral is at least one of sodium and potassium.
In a second aspect, the present invention provides a process for preparing the above composition, comprising the steps of:
(1) pretreatment: weighing the composite mineral substance and citric acid according to a ratio, and adding water to completely dissolve the composite mineral substance and the citric acid to form a buffer solution;
(2) weighing: adding maltodextrin, crystalline fructose and oligosaccharide into a mixing tank according to a ratio, uniformly stirring, then adding a buffer solution, and uniformly stirring;
(3) homogenizing: passing the prepared solution through a homogenizer;
(4) and (3) sterilization: sterilizing at high temperature for a short time, cooling, adding food essence, and stirring;
(5) filling: and (4) performing quantitative filling and sealing by adopting sterile filling to obtain the medical electrolyte composition.
In a preferred embodiment of the method for preparing the composition of the present invention, in the step (2), the stirring time is 5 to 10 min.
In the preferred embodiment of the preparation method of the composition of the present invention, in the step (4), the temperature for the high-temperature short-time sterilization is 125 to 135 ℃, and the time is 10 to 30S.
Compared with the prior art, the invention has the beneficial effects that: the composition of the invention mixes monosaccharide (fructose) and polysaccharide (maltodextrin and oligosaccharide) for use, and various sugars are absorbed by human body one by one to slowly release energy by reducing the content of the monosaccharide, so that blood sugar rises slowly after drinking, and the duration of satiety is prolonged. The composition of the invention can smooth blood sugar of a patient before operation, reduce hunger sensation and facilitate defecation and cleaning of intestinal tracts so as to improve and maintain the living state of the patient and reduce fear and tension of the patient before operation. In addition, the insulin resistance response of the patient after the operation has no obvious difference from the effect of the traditional intestinal tract preparation method.
Detailed Description
To better illustrate the objects, aspects and advantages of the present invention, the present invention will be further described with reference to specific examples.
Example 1
A medical electrolyte composition comprises the following components in percentage by mass: 9.8% of maltodextrin, 2.5% of crystalline fructose, 1.5% of galacto-oligosaccharide, 0.15% of compound mineral (sodium citrate: potassium citrate: 1: 2), 0.5% of citric acid, 0.01% of food essence and the balance of water.
The preparation method comprises the following steps:
(1) pretreatment: weighing the composite mineral substance and citric acid according to a ratio, and adding water to completely dissolve the composite mineral substance and the citric acid to form a buffer solution;
(2) weighing: adding maltodextrin, crystalline fructose and oligosaccharide into a mixing tank according to a ratio, uniformly stirring, then adding a buffer solution, and uniformly stirring;
(3) homogenizing: passing the prepared solution through a homogenizer;
(4) and (3) sterilization: sterilizing at high temperature of 125-135 ℃ for 15S in a short time, cooling, adding food essence, and uniformly stirring;
(5) filling: quantitative filling and sealing are carried out by adopting sterile filling, and the medical electrolyte composition which can provide 211kJ energy per 100mL is prepared.
Example 2
A medical electrolyte composition comprises the following components in percentage by mass: 10.1% of maltodextrin, 2.6% of crystalline fructose, 0.4% of xylo-oligosaccharide, 0.15% of compound mineral (sodium citrate: potassium citrate: 1), 0.5% of citric acid, 0.01% of food essence and the balance of water.
The preparation method is the same as that of example 1.
Example 3
A medical electrolyte composition comprises the following components in percentage by mass: 9.8% of maltodextrin, 2.6% of crystalline fructose, 1.25% of oligomannose, 0.15% of compound mineral (sodium citrate: potassium citrate: 1: 3), 0.5% of citric acid, 0.01% of food essence and the balance of water.
The preparation method is the same as that of example 1.
Example 4
A medical electrolyte composition comprises the following components in percentage by mass: 9.8% of maltodextrin, 2.55% of crystalline fructose, 1.1% of resistant dextrin, 0.15% of compound mineral (sodium citrate: potassium citrate: 1), 0.5% of citric acid, 0.01% of food essence and the balance of water.
The preparation method is the same as that of example 1.
Example 5
A medical electrolyte composition comprises the following components in percentage by mass: 8% of maltodextrin, 2% of crystalline fructose, 0.3% of resistant dextrin, 0.1% of compound mineral (sodium citrate: potassium citrate: 1), 0.2% of citric acid and the balance of water.
The preparation method is the same as that of example 1.
Example 6
A medical electrolyte composition comprises the following components in percentage by mass: 22% of maltodextrin, 6% of crystalline fructose, 3% of resistant dextrin, 0.7% of compound mineral (sodium citrate: 1: 3 of potassium citrate), 1% of citric acid, 0.05% of food essence and the balance of water.
The preparation method is the same as that of example 1.
Comparative example 1
A medical electrolyte composition comprises the following components in percentage by mass: 2.5% of crystalline fructose, 1.5% of galacto-oligosaccharide, 0.15% of compound mineral (sodium citrate: potassium citrate: 1), 0.5% of citric acid, 0.01% of food essence and the balance of water.
The preparation method is the same as that of example 1.
Comparative example 2
A medical electrolyte composition comprises the following components in percentage by mass: 9.8% of maltodextrin, 1.5% of galacto-oligosaccharide, 0.15% of compound mineral (sodium citrate: potassium citrate: 1: 2), 0.5% of citric acid, 0.01% of food essence and the balance of water.
The preparation method is the same as that of example 1.
Comparative example 3
A medical electrolyte composition comprises the following components in percentage by mass: 8% of maltodextrin, 6% of crystalline fructose, 4% of galacto-oligosaccharide, 0.15% of compound mineral (sodium citrate: potassium citrate: 1: 3), 0.5% of citric acid, 0.01% of food essence and the balance of water.
The preparation method is the same as that of example 1.
Examples of effects
(1) Action on blood sugar
The compositions prepared in examples 1 to 6 and comparative examples 1 to 3 were tested for their effect on blood glucose. Examples 1 to 6, comparative examples 1 to 3, and 200mL of 10% glucose solution (glucose, sodium chloride) were divided into 10 groups, 6 healthy volunteers were administered to each group, blood glucose values at 5 points were measured, and the average value of each group was determined. The test results are shown in table 1.
TABLE 1
The blood glucose level after administration of 10% glucose solution was high, and the blood glucose level of the composition prepared in examples 1 to 6 was low and the trend was moderate, wherein the energy of the composition prepared in example 1 was 211kJ/100g, and the blood glucose level was low and the trend was moderate. Comparative example 1 did not contain maltodextrin, comparative example 2 did not contain crystalline fructose, the mass percentages of the components of comparative example 3 were not all within the range of the present invention, and the energy value or effect of smoothing blood glucose was not as good as the present invention.
(2) Hunger sensation test
Examples 1 to 6, comparative examples 1 to 3, and 200mL of 10% glucose solution (glucose, sodium chloride) were divided into 10 groups, 6 healthy volunteers were administered to each group, and the average time after administration was evaluated to determine whether they were in a sense of stool or hunger, and the average value was taken for each group. The test results are shown in table 2.
TABLE 2
| Time (h) to feel hunger | Time (h) of feeling of defecation | |
| 10% glucose solution | 2.52 | 2.60 |
| Example 1 | 2.80 | 2.20 |
| Example 2 | 2.82 | 2.23 |
| Example 3 | 2.81 | 2.22 |
| Example 4 | 2.81 | 2.20 |
| Example 5 | 2.65 | 2.57 |
| Example 6 | 3.22 | 2.15 |
| Comparative example 1 | 2.10 | 2.37 |
| Comparative example 2 | 2.74 | 2.25 |
| Comparative example 3 | 2.96 | 2.18 |
As can be seen from Table 2, after taking 10% glucose solution, the time for satiety was short and the time for defecation was long; after the compositions prepared in examples 1-6 are taken, the time for feeling full is longer, and the time for feeling convenient is shorter. From the combined effects on blood glucose and hunger sensation tests, example 1 has good energy values, a blood glucose-smoothing effect, and a prolonged feeling of satiety, i.e. when the composition comprises the following components in mass percent: the maltodextrin has the advantages of 9.8 percent, 2.5 percent of crystalline fructose, 1.5 percent of oligosaccharide, 0.15 percent of compound mineral, 0.5 percent of citric acid, 0.01 percent of food essence and the balance of water, and has better effect.
Finally, it should be noted that the above embodiments are only used for illustrating the technical solutions of the present invention and not for limiting the protection scope of the present invention, and although the present invention is described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications or equivalent substitutions can be made on the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention.
Claims (7)
1. The medical electrolyte composition is characterized by comprising the following components in percentage by mass: 8 to 22 percent of maltodextrin, 2 to 6 percent of crystalline fructose, 0.3 to 3 percent of oligosaccharide, 0.1 to 0.7 percent of compound mineral, 0.2 to 1 percent of citric acid, 0 to 0.05 percent of food essence and the balance of water.
2. The composition according to claim 1, wherein the composition comprises the following components in percentage by mass: 9.8% of maltodextrin, 2.5% of crystalline fructose, 1.5% of oligosaccharide, 0.15% of compound mineral, 0.5% of citric acid, 0.01% of food essence and the balance of water.
3. The composition of claim 1 or 2, wherein the oligosaccharide is at least one of galacto-oligosaccharide, mannose-oligosaccharide, xylose-oligosaccharide, resistant dextrin.
4. The composition of claim 1 or 2, wherein the complex mineral is at least one of sodium and potassium.
5. A process for the preparation of a composition according to claims 1 to 4, comprising the steps of:
(1) pretreatment: weighing the composite mineral substance and citric acid according to a ratio, and adding water to completely dissolve the composite mineral substance and the citric acid to form a buffer solution;
(2) weighing: adding maltodextrin, crystalline fructose and oligosaccharide into a mixing tank according to a ratio, uniformly stirring, then adding a buffer solution, and uniformly stirring;
(3) homogenizing: passing the prepared solution through a homogenizer;
(4) and (3) sterilization: sterilizing at high temperature for a short time, cooling, adding food essence, and stirring;
(5) filling: and (4) performing quantitative filling and sealing by adopting sterile filling to obtain the medical electrolyte composition.
6. The method for preparing the composition according to claim 5, wherein the stirring time in the step (2) is 5 to 10 min.
7. The method for preparing the composition according to claim 5, wherein the temperature for the high-temperature short-time sterilization in the step (4) is 125 to 135 ℃ and the time is 10 to 30 seconds.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911363862.XA CN111011863A (en) | 2019-12-26 | 2019-12-26 | Medical electrolyte composition and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911363862.XA CN111011863A (en) | 2019-12-26 | 2019-12-26 | Medical electrolyte composition and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111011863A true CN111011863A (en) | 2020-04-17 |
Family
ID=70214507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911363862.XA Pending CN111011863A (en) | 2019-12-26 | 2019-12-26 | Medical electrolyte composition and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111011863A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113209132A (en) * | 2021-04-06 | 2021-08-06 | 鲲鱼健康药业江苏有限公司 | Electrolyte preparation product for special medical application and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104940226A (en) * | 2015-07-15 | 2015-09-30 | 邱小文 | Nutritional supplementing combination, application thereof and nutritional supplement with same |
| CN105747208A (en) * | 2016-02-23 | 2016-07-13 | 江苏正大丰海制药有限公司 | Oral glucose liquid composition |
| CN107836610A (en) * | 2017-10-24 | 2018-03-27 | 广东君悦营养医学有限公司 | A kind of energy drink drunk suitable for operation consent patient and preparation method thereof |
| CN108338984A (en) * | 2018-02-26 | 2018-07-31 | 量子高科(中国)生物股份有限公司 | Composition with gut purge effect and preparation method thereof and the application in carbohydrate-binding module spy cures formula food |
-
2019
- 2019-12-26 CN CN201911363862.XA patent/CN111011863A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104940226A (en) * | 2015-07-15 | 2015-09-30 | 邱小文 | Nutritional supplementing combination, application thereof and nutritional supplement with same |
| CN105747208A (en) * | 2016-02-23 | 2016-07-13 | 江苏正大丰海制药有限公司 | Oral glucose liquid composition |
| CN107836610A (en) * | 2017-10-24 | 2018-03-27 | 广东君悦营养医学有限公司 | A kind of energy drink drunk suitable for operation consent patient and preparation method thereof |
| CN108338984A (en) * | 2018-02-26 | 2018-07-31 | 量子高科(中国)生物股份有限公司 | Composition with gut purge effect and preparation method thereof and the application in carbohydrate-binding module spy cures formula food |
Non-Patent Citations (2)
| Title |
|---|
| 光冈知足: "《肠内革命》", 31 January 2016, 湖北科学技术出版社, pages: 108 * |
| 陈福玉等: "《食品化学》", 31 May 2017, 中国质检出版社, pages: 38 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113209132A (en) * | 2021-04-06 | 2021-08-06 | 鲲鱼健康药业江苏有限公司 | Electrolyte preparation product for special medical application and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6985231B2 (en) | Use of purified 2'-fucosyllactoce, 3-fucosyllactose, and lactodifucotetraose as prebiotics | |
| CN1731938B (en) | Prebiotic compositions | |
| Cummings et al. | Gastrointestinal effects of prebiotics | |
| CN101772308B (en) | Use of probiotics and fibers for diarrhoea | |
| CN107019701B (en) | Methods of using human milk oligosaccharides to reduce the incidence of necrotizing enterocolitis in infants, toddlers, or children | |
| EP1355542B2 (en) | Nutritional composition with health promoting action containing oligosaccharides | |
| CN101925307B (en) | High energy liquid enteral nutritional composition | |
| EP1588629B1 (en) | Matrix-forming composition containing pectin | |
| RU2471375C2 (en) | Paediatric mixture of food fibres | |
| TW201233334A (en) | Human milk oligosaccharides to promote growth of beneficial bacteria | |
| JP4626752B2 (en) | Novel uses of carbohydrates and compositions | |
| CN113662199A (en) | Human milk oligosaccharides for preventing gastrointestinal damage and/or promoting gastrointestinal healing | |
| Heavey et al. | The gut microflora of the developing infant: microbiology and metabolism | |
| CN114761023A (en) | HMO mixtures | |
| CN111011863A (en) | Medical electrolyte composition and preparation method thereof | |
| CN116549494B (en) | Beta-1, 3/alpha-1, 3-glucan compound composition with bowel relaxing function and preparation method and application thereof | |
| JP2007131541A (en) | Agent for promoting release of growth hormone | |
| EP2928325A1 (en) | Nutritional composition with non digestible oligosaccharides | |
| CN114599232A (en) | Composition comprising 2' -fucosyllactose for preventing asthma | |
| CN108936609B (en) | Nutritional preparation for elderly patients with swallowing dysfunction | |
| Morais et al. | Gestational Diabetes and Microbiota: role of probiotic intervention | |
| Rastall | Galacto‐oligosaccharides as prebiotic food ingredients | |
| CN115067504B (en) | Special medical food for intestinal tract preparation and preparation method thereof | |
| CN109965172A (en) | A kind of electrolyte solid beverage | |
| Li | Study on the Application of Dietary Fiber on Special Medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 529040 No.133, Gaoxin West Road, Gaoxin District, Jiangmen City, Guangdong Province Applicant after: Smart Pharmaceutical Technology Co.,Ltd. Address before: 529040 No.133, Gaoxin West Road, Gaoxin District, Jiangmen City, Guangdong Province Applicant before: QUANTUM HI-TECH(CHINA) BIOLOGICAL Co.,Ltd. |
|
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20220613 Address after: 529040 No. 133, Gaoxin West Road, Gaoxin District, Jiangmen City, Guangdong Province (one address with multiple photos) Applicant after: Quantum hi tech (Guangdong) biology Co.,Ltd. Address before: 529040 No.133, Gaoxin West Road, Gaoxin District, Jiangmen City, Guangdong Province Applicant before: Smart Pharmaceutical Technology Co.,Ltd. |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200417 |